Hepion Pharmaceuticals Plunges 13.93% on Reverse Stock Split

On April 10, 2025, Hepion Pharmaceuticals, Inc. (HEPA) experienced a significant drop of 13.93% in pre-market trading, reflecting a notable shift in investor sentiment towards the biopharmaceutical company.

Hepion Pharmaceuticals, Inc. recently announced a 1-for-50 reverse stock split, a strategic move aimed at maintaining its listing on the Nasdaq. This decision is crucial as it helps the company meet the exchange's minimum bid requirement of $1.00 per share. The reverse split will dramatically reduce the number of outstanding shares, which could impact the stock's trading dynamics and volatility.

Analysts have expressed optimism about Hepion Pharmaceuticals' future prospects. The average price target for the stock is set at $30.00, indicating a substantial potential upside from its current market price. This optimistic outlook is supported by an "Outperform" rating from analysts, suggesting that the company's strategic initiatives and financial adjustments could lead to significant growth in the long term.